About: Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication
Creator	Kusov, Yuri Harak, Christian Lohmann, Volker Schult, Philipp Esser-Nobis, Katharina
Source	PMC
abstract	Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive‐strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper insight into determinants of replication, persistence, and treatment, we established a homogenous cell‐culture model allowing a thorough comparison of RNA replication of both viruses. By screening different human liver‐derived cell lines with subgenomic reporter replicons of HAV as well as of different HCV genotypes, we found that Huh7‐Lunet cells supported HAV‐ and HCV‐RNA replication with similar efficiency and limited interference between both replicases. HAV and HCV replicons were similarly sensitive to interferon (IFN), but differed in their ability to establish persistent replication in cell culture. In contrast to HCV, HAV replicated independently from microRNA‐122 and phosphatidylinositol 4‐kinase IIIα and β (PI4KIII). Both viruses were efficiently inhibited by cyclosporin A and NIM811, a nonimmunosuppressive analog thereof, suggesting an overlapping dependency on cyclophilins for replication. However, analysis of a broader set of inhibitors revealed that, in contrast to HCV, HAV does not depend on cyclophilin A, but rather on adenosine‐triphosphate–binding cassette transporters and FK506‐binding proteins. Finally, silibinin, but not its modified intravenous formulation, efficiently inhibited HAV genome replication in vitro, suggesting oral silibinin as a potential therapeutic option for HAV infections. Conclusion: We established a cell‐culture model enabling comparative studies on RNA replication of HAV and HCV in a homogenous cellular background with comparable replication efficiency. We thereby identified new host cell targets and potential treatment options for HAV and set the ground for future studies to unravel determinants of clearance and persistence. (Hepatology 2015;62:397–408
has issue date	2015-05-20(xsd:dateTime)
bibo:doi	10.1002/hep.27847
bibo:pmid	25866017
has license	no-cc
sha1sum (hex)	65aebb15c6e84ac54d680ab2baf76158559b722b
schema:url	https://doi.org/10.1002/hep.27847
resource representing a document's title	Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication
has PubMed Central identifier	PMC7165973
has PubMed identifier	25866017
schema:publication	Hepatology
resource representing a document's body	covid:65aebb15c6e84ac54d680ab2baf76158559b722b#body_text
is schema:about of	named entity 'potential' named entity 'HCV genotypes' named entity 'cassette' named entity 'human' named entity 'cleared' named entity 'set' named entity 'model' named entity 'Hepatitis C Virus' named entity 'DOES NOT' named entity 'REPORTER' named entity '2015' named entity 'INHIBITED' named entity 'A CELL' named entity 'FK506' named entity 'GENOTYPES' named entity 'TREATMENT OPTIONS' named entity 'BINDING' named entity 'TREATMENT' named entity 'POSITIVE' named entity 'ESTABLISHED' named entity 'HOMOGENOUS' named entity 'DEPEND' named entity 'RNA REPLICATION' named entity 'POTENTIAL' named entity 'OUTCOMES' named entity 'SENSITIVE TO' named entity 'GROUND' named entity 'HCV' named entity 'enabling' named entity 'set' named entity 'persistence' named entity 'insight' named entity 'persistence' named entity 'limited' named entity 'HCV' named entity 'efficiency' named entity 'model' named entity 'intravenous' named entity '2015' named entity 'background' named entity 'Therapy' named entity 'Virus' named entity 'Hepatitis A' named entity 'RNA viruses' named entity 'RNA replication' named entity 'cell lines' named entity 'HAV' named entity 'HAV' named entity 'cyclosporin' named entity 'analog' named entity 'intravenous' named entity 'HCV' named entity 'HEPATOLOGY' named entity 'HAV' named entity 'Huh7' named entity 'microRNA-122' named entity 'cyclophilins' named entity 'HCV' named entity 'hepatitis C virus' named entity 'HCV' named entity 'HCV genotypes' named entity 'Hepatitis A Virus' named entity 'Hepatitis C Virus' named entity 'interferon' named entity 'ABC transporters' named entity 'infection' named entity 'Huh7' named entity 'lipid kinase' named entity 'electroporation' named entity 'HCV' named entity 'HCV' named entity 'CsA' named entity 'HCV' named entity 'replicons' named entity 'HAV' named entity 'viruses' named entity 'Genomics'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software